Loading
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Latest quote
$16.51
−$0.365 · -2.16%
After-hours
$16.51
$0.00 · 0.00%
Sep 14, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Day range
Current $16.51
52-week range
Current $16.51
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
55
Fair Value
Sentiment
66
Bullish
Risk
40
Moderate Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Day range
Current $16.51
52-week range
Current $16.51
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 858K USD | 636K USD | — | — | — |
| Cost of goods sold | 92K USD | 39.51M USD | 150K USD | — | 109K USD |
| Gross profit | 766K USD | −38.87M USD | −150K USD | — | −109K USD |
| Research and development | 19.6M USD | 41.51M USD | 53.54M USD | 40.69M USD | 26.91M USD |
| Selling, general, and administrative | 14.33M USD | 18.33M USD | 25.39M USD | 27.2M USD | 18.74M USD |
| Operating expenses | 28.83M USD | 21.63M USD | 78.93M USD | 67.88M USD | 45.65M USD |
| Interest income | 2.19M USD | 4.22M USD | 6.15M USD | 1.96M USD | 54K USD |
| Interest expense | — | — | — | — | 10K USD |
| Depreciation and amortization | 92K USD | 131K USD | 150K USD | 167K USD | 109K USD |
| Operating income | −28.06M USD | −60.5M USD | −78.93M USD | −67.88M USD | −45.65M USD |
| Net income | −8.98M USD | −57.78M USD | −74.56M USD | −66.65M USD | −47.01M USD |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 6, 2026 | 1:8 | — | — |
Effective Feb 6, 2026
1:8
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.14M0.00%2.3T USD0.03%$374.68-0.43%
Vanguard Extended Market ETFVXF516.88K0.00%93.7B USD0.05%$236.92-0.35%
iShares Micro-Cap ETFIWC198.35K0.01%1.44B USD0.60%$190.92+0.04%
Dimensional - US Small Cap ETFDFAS111.81K0.00%15.49B USD0.26%$80.16-0.45%
U.S. Micro Cap Portfolio ETFDFMC98.67K0.00%7.73B USD0.43%$58.823-0.52%
Avantis U.S. Small Cap Equity ETFAVSC26.16K—3.09B USD0.25%$71.285-0.27%
Dimensional - US Core Equity 1 ETFDCOR11.46K0.00%3.58B USD0.14%$83.57-0.41%
Dimensional - US Core Equity 2 ETFDFAC9.68K0.00%49.17B USD0.17%$44.95-0.47%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCDimensional - US Core Equity 1 ETFDCORDimensional - US Core Equity 2 ETFDFACAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
